To Explore the Potential Inhibitors against Multitarget Proteins of COVID 19 using In Silico Study
- URL: http://arxiv.org/abs/2409.16486v1
- Date: Tue, 24 Sep 2024 22:19:56 GMT
- Title: To Explore the Potential Inhibitors against Multitarget Proteins of COVID 19 using In Silico Study
- Authors: Imra Aqeel,
- Abstract summary: The global pandemic due to emergence of COVID 19 has created the unrivaled public health crisis.
We used the combination of molecular docking and machine learning regression approaches to explore the potential inhibitors for the treatment of COVID 19.
We proposed five novel promising inhibitors with their respective Zinc IDs ZINC (3873365, 85432544, 8214470, 85536956, and 261494640) within the range of -19.7 kcal/mol to -12.6 kcal/mol.
- Score: 0.0
- License: http://creativecommons.org/licenses/by/4.0/
- Abstract: The global pandemic due to emergence of COVID 19 has created the unrivaled public health crisis. It has huge morbidity rate never comprehended in the recent decades. Researchers have made many efforts to find the optimal solution of this pandemic. Progressively, drug repurposing is an emergent and powerful strategy with saving cost, time, and labor. Lacking of identified repurposed drug candidates against COVID 19 demands more efforts to explore the potential inhibitors for effective cure. In this study, we used the combination of molecular docking and machine learning regression approaches to explore the potential inhibitors for the treatment of COVID 19. We calculated the binding affinities of these drugs to multitarget proteins using molecular docking process. We perform the QSAR modeling by employing various machine learning regression approaches to identify the potential inhibitors against COVID 19. Our findings with best scores of R2 and RMSE demonstrated that our proposed Decision Tree Regression (DTR) model is the most appropriate model to explore the potential inhibitors. We proposed five novel promising inhibitors with their respective Zinc IDs ZINC (3873365, 85432544, 8214470, 85536956, and 261494640) within the range of -19.7 kcal/mol to -12.6 kcal/mol. We further analyzed the physiochemical and pharmacokinetic properties of these most potent inhibitors to examine their behavior. The analysis of these properties is the key factor to promote an effective cure for public health. Our work constructs an efficient structure with which to probe the potential inhibitors against COVID-19, creating the combination of molecular docking with machine learning regression approaches.
Related papers
- Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
Conditional generation based on the target IC50 score can obtain a more effective sampling space.
Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
arXiv Detail & Related papers (2024-05-23T13:22:17Z) - Quantum Computing-Enhanced Algorithm Unveils Novel Inhibitors for KRAS [10.732020360180773]
We introduce a quantum-classical generative model that seamlessly integrates the power of quantum algorithms trained on a 16-qubit IBM quantum computer.
Our work shows for the first time the use of a quantum-generative model to yield experimentally confirmed biological hits.
arXiv Detail & Related papers (2024-02-13T04:19:06Z) - Drug Repurposing Targeting COVID-19 3CL Protease using Molecular Docking and Machine Learning Regression Approach [0.15346678870160887]
The COVID-19 pandemic has initiated a global health emergency, with an exigent need for effective cure.
We screened the 5903 approved drugs for their inhibition by targeting the main protease 3CL of SARS-CoV-2.
We employed several machine learning regression approaches for QSAR modeling to find out some potential drugs with high binding affinities.
arXiv Detail & Related papers (2023-05-25T05:34:39Z) - Drug Synergistic Combinations Predictions via Large-Scale Pre-Training
and Graph Structure Learning [82.93806087715507]
Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation.
Deep learning models have emerged as an efficient way to discover synergistic combinations.
Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
arXiv Detail & Related papers (2023-01-14T15:07:43Z) - Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a
Single, Sequence-Guided Deep Generative Framework [47.14853881703749]
We demonstrate the broad utility of a single deep generative framework toward discovering novel drug-like inhibitor molecules.
To perform target-aware design, the framework employs a target sequence-conditioned sampling of novel molecules from a generative model.
The most potent spike RBD inhibitor also emerged as a rare non-covalent antiviral with broad-spectrum activity against several SARS-CoV-2 variants.
arXiv Detail & Related papers (2022-04-19T17:59:46Z) - Improved Drug-target Interaction Prediction with Intermolecular Graph
Transformer [98.8319016075089]
We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture.
Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively.
IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
arXiv Detail & Related papers (2021-10-14T13:28:02Z) - An Explainable-AI approach for Diagnosis of COVID-19 using MALDI-ToF
Mass Spectrometry [0.9250974571641537]
Severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) caused a global pandemic and immensely affected the global economy.
Recently, multiple alternative platforms for testing coronavirus disease 2019 (COVID-19) have been published that show high agreement with current gold standard real-time polymerase chain reaction (RT-PCR) results.
These new methods do away with nasopharyngeal (NP) swabs, eliminate the need for complicated reagents, and reduce the burden on RT-PCR test reagent supply.
In the present work, we have designed an artificial intelligence-based (AI) testing method to provide confidence in the results.
arXiv Detail & Related papers (2021-09-28T23:29:31Z) - A Novel Framework Integrating AI Model and Enzymological Experiments
Promotes Identification of SARS-CoV-2 3CL Protease Inhibitors and
Activity-based Probe [8.35958386389992]
We propose a novel framework, named AIMEE, to identify inhibitors against 3CL protease of SARS-CoV-2.
From a bioactive chemical library, we have conducted two rounds of experiments and identified six novel inhibitors with a hit rate of 29.41%.
We explored the interpretability of the central model in AIMEE, mapping the deep learning extracted features to domain knowledge of chemical properties.
arXiv Detail & Related papers (2021-05-29T06:23:05Z) - PaccMann$^{RL}$ on SARS-CoV-2: Designing antiviral candidates with
conditional generative models [2.0750380105212116]
With the fast development of COVID-19 into a global pandemic, scientists around the globe are desperately searching for effective antiviral therapeutic agents.
We propose a deep learning framework for conditional de novo design of antiviral candidate drugs tailored against given protein targets.
arXiv Detail & Related papers (2020-05-27T11:30:15Z) - Accelerating Antimicrobial Discovery with Controllable Deep Generative
Models and Molecular Dynamics [109.70543391923344]
CLaSS (Controlled Latent attribute Space Sampling) is an efficient computational method for attribute-controlled generation of molecules.
We screen the generated molecules for additional key attributes by using deep learning classifiers in conjunction with novel features derived from atomistic simulations.
The proposed approach is demonstrated for designing non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum potency.
arXiv Detail & Related papers (2020-05-22T15:57:58Z) - CogMol: Target-Specific and Selective Drug Design for COVID-19 Using
Deep Generative Models [74.58583689523999]
We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins.
CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme.
CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
arXiv Detail & Related papers (2020-04-02T18:17:20Z)
This list is automatically generated from the titles and abstracts of the papers in this site.
This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.